

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/008,062	10/19/2001	David Rizzieri	5405-252	5735
20792 75	90 10/28/2005		EXAMINER	
MYERS BIGEL SIBLEY & SAJOVEC			HARRIS, ALANA M	
PO BOX 37428 RALEIGH, NC 27627			ART UNIT	PAPER NUMBER
	,		1643	
			DATE MAILED: 10/28/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Applicant(s) Application No. 10/008,062 RIZZIERI ET AL. Interview Summary Art Unit Examiner 1643 Alana M. Harris, Ph.D. All participants (applicant, applicant's representative, PTO personnel): (3) David Rizzieri. (1) Alana M. Harris, Ph.D. (4) Darell Bigner and (5) Michael Zalutsky. (2) Shawna C. Lemon. Date of Interview: 25 October 2005. Type: a) ☐ Telephonic b) ☐ Video Conference 2) applicant's representative c) Personal [copy given to: 1) applicant e) No. Exhibit shown or demonstration conducted: d) Yes If Yes, brief description: \_\_\_\_\_. Claim(s) discussed: 1-6 and 8-22. Identification of prior art discussed: U.S. Patent number 5,624,659 (04/29/97, IDS reference) and Rizzieri et al. (Blood 94(10), Part 2, Supplement 1: 4339, Abstract #4339, November 1999, IDS reference). Agreement with respect to the claims f) was reached. g) was not reached. h) $\times$ N/A. Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet. (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet. Examiner Note: You must sign this form unless it is an Examiner's signature, if required Attachment to a signed Office action.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: All participants discussed the outstanding rejections, 11s, 1st and 103. Applicants described their claimed invention noting there was intravenous administration of the monoclonal antibody (mAb) coupled to the 131-I isotope and surprisingly the said radioisotope retained its biological activity and therapeutic effectiveness for a prolonged period of time. The Exr. expressed to Applicants as claims currently read the instant rejections would still be applicable and any changes to the claims should be fully supported by the specification. Also noteworthy was the Exr.'s contention that the said administration did not impart novelty or non-obviousness to the claims and the results are not considered unexpected in lieu of the motivation provided in both references, i.e. patent, column 4, lines 16-26 and Examples implementing 131-I conjugated to mAb 816C6, as well as Rizzieri abstract, last paragraph..